3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Brain Neoplasms
2
Vaping
1
Tobacco Use Disorder
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Endometrial Neoplasms
1
Advanced Solid Tumor
1
Interventions
Injections
13
pembrolizumab
10
tislelizumab
9
toripalimab
6
atezolizumab
4
Nivolumab
4
Carboplatin
3
trastuzumab deruxtecan
2
olaparib
2
lenvatinib
2
Pemetrexed
2
Paclitaxel
2
Oxaliplatin
2
Gemcitabine
2
Fluorouracil
2
Docetaxel
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Bevacizumab
2
zimberelimab
1
talazoparib
1
spartalizumab
1
sotorasib
1
serabelisib
1
penpulimab
1
niraparib
1
nedaplatin
1
mirdametinib
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumor
×
BID protein, human
×
1 year
×
Clear all
NCT06560632
2026-01-16
POLAR
Repare Therapeutics
Phase 1
Terminated
26 enrolled
14 charts